# Fresenius Medical Care AG share price today (Fresenius Medical Care AG, FMS)

> Fresenius Medical Care AG's earnings have grown faster than its share price. Earnings per share grew +83.6% in a year while the price moved −19.0%. FMS · Healthcare · Medical Care Facilities · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/fms

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $21.73 (−19.0% in a year)
- P/E: 11.6×, over 4.6 years
- Revenue (Jun 2026): $4.9 B (+1.4% on a year ago)
- Profit (Jun 2026): $218 M (−3.1% on a year ago)
- Operating margin: 10.8% (+2.6 points on a year ago)
- ROE: 7%, FY25
- ROIC: 6.3%, against a 5.6% cost of capital: +0.7 points

The main question: yearly earnings per share moved +83.6% while the share price moved −19.0%. ## What is the Fresenius Medical Care AG share price today? Fresenius Medical Care AG's share price was $21.73 at the close on 3 November 2026. It has been falling for 11 weeks. That is 5.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $21 and $26, and at that close it sat 15% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 10 weeks running. Over the last 10 years the share price moved −50% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 28 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Fresenius Medical Care AG pay? Fresenius Medical Care AG has 3 quarters of declared dividends on file, too few for a 12-month total. The most recent declaration was $1.49 for Dec 2025. Fresenius Medical Care AG declared a dividend in 3 of the last 12 reported quarters, most recently $1.49 for Dec 2025. That is fewer than four quarters, so no 12-month total is shown. ## Which stock lists is Fresenius Medical Care AG on? Fresenius Medical Care AG is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Fresenius Medical Care AG profitable? Fresenius Medical Care AG earned $218 M of net profit in the Jun 2026 quarter, −3.1% on the same quarter a year earlier. Full-year FY25 profit was $978 M. Over 4 years profit has grown 0.2% a year on average. That is 4.5% of the quarter's revenue. The same quarter a year earlier earned $225 M. For the full year, FY25 profit was $978 M (+81.9% on the year before). Why profit moved: revenue changed +1.4% on a year earlier and the margin moved +2.6 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +98.1% and revenue −0.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Fresenius Medical Care AG make, and is it growing? Fresenius Medical Care AG reported $4.9 B of revenue in the Jun 2026 quarter, +1.4% on the same quarter a year earlier. Over 4 years it has grown 2.7% a year on average. The last full year, FY25, came in at $19.6 B. The last four reported quarters add to $19.4 B. FY25 revenue was $19.6 B, +1.5% on the year before. Recent pace: the last four quarters grew −0.4% on average, against 2.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −0.5%, against +0.0% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +42.9%, against +33.0% a year (accelerating). ## How much of every $100 of sales does Fresenius Medical Care AG keep? Fresenius Medical Care AG's operating margin was 10.8% in the Jun 2026 quarter, 2.6 percentage points higher than the same quarter a year ago. Across 5 years it has been between 7.8% and 10.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.6 percentage points on the year while gross margin changed +1.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Fresenius Medical Care AG's profit turning into cash? Over the last 3 years, 382% of Fresenius Medical Care AG's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $2.7 B of operating cash against $978 M of profit. After $915 M of spending on assets, $1.8 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Fresenius Medical Care AG's cash go? Fresenius Medical Care AG does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.3 B on assets over the last 3 years. Averaged over those years that is 3.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.3 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Fresenius Medical Care AG's P/E ratio, and how does it compare with its own history? Fresenius Medical Care AG's P/E is 11.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +83.6% while the price moved −19.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +7.6% a year; about +29.5% a year came from earnings growth and about −21.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Fresenius Medical Care AG business getting better or worse? Fresenius Medical Care AG's business is giving mixed signals. Growth has been steadily positive, but ROCE at 8.0% is below the 15% level needed to call it steady growth. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Fresenius Medical Care AG earn on its capital? Fresenius Medical Care AG earned a ROE of 7% in FY25. That is up from a low of 3% in FY23. Its return on capital used (ROIC) is 0.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 5.0% net margin and 0.63× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 5.0% net margin × 0.63× asset turnover × 2.17× leverage (assets divided by equity) ≈ 6.8% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 6.3% − 5.6% = +0.7 percentage points. The 5.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Fresenius Medical Care AG have too much debt? Fresenius Medical Care AG has total debt of $11.0 B against shareholder equity of $13.5 B as of Jun 2026, so its debt is 0.81× its equity. Year by year, that ratio went from 0.95 in FY21 to 0.76 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Fresenius Medical Care AG shareholding pattern? We have no ownership or short-position figures for Fresenius Medical Care AG, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 4.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Fresenius Medical Care AG from balance-sheet trouble? For Fresenius Medical Care AG, the Z-score is 1.78. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.78 is inside the danger zone, so the balance sheet is a real risk. ## How does Fresenius Medical Care AG rank in its industry? 50.7 out of 100, rank 15 of 30 in Medical Care Facilities, with 81% of the evidence available. Fresenius Medical Care AG scores 50.7 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.9 + 11.1 + 15.3 + 2.4 = 50.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Fresenius Medical Care AG compared with? Fresenius Medical Care AG ranks 15 of 30 Medical Care Facilities companies on the 4-Factor Sector Score, with 50.7 out of 100. 1. [Concentra Group Holdings Parent, Inc.](https://www.sectoralpha.in/us/stocks/con) CON · leader · Most evidence points up · 81% evidence 71.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 14% · Profit 32.6% · Operating margin change 2.3 points · 83% evidence Capital efficiency 16.6/25 · ROCE 14.5% · Operating margin 19.3% · 76% evidence Valuation 13.0/20 · P/E 19.5× · PEG 0.65 · 65% evidence Relative strength 17.3/20 · Lead over its industry 18.3% · Lead over S&P 500 41.8% · 1 year 107.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.4 + 16.6 + 13 + 17.3 = 71.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Tenet Healthcare Corporation](https://www.sectoralpha.in/us/stocks/thc) THC · losing its lead · Evidence leans up · 81% evidence 64.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 5.4% · Profit 32.4% · Operating margin change 2.1 points · 83% evidence Capital efficiency 17.1/25 · ROCE 15% · Operating margin 18.2% · 76% evidence Valuation 15.3/20 · P/E 7.2× · PEG 0.35 · 65% evidence Relative strength 11.1/20 · Lead over its industry -3.8% · Lead over S&P 500 16.9% · 1 year 29.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21 + 17.1 + 15.3 + 11.1 = 64.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [AMN Healthcare Services, Inc.](https://www.sectoralpha.in/us/stocks/amn) AMN · breaking out · Evidence leans up · 64% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 23.9% · Profit n/a · Operating margin change 3.4 points · 62% evidence Capital efficiency 9.1/25 · ROCE 10.1% · Operating margin 4% · 76% evidence Valuation 10.4/20 · P/E 12× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.8% · Lead over S&P 500 63.5% · 1 year 153.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.3 + 9.1 + 10.4 + 19.6 = 64.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Pediatrix Medical Group, Inc.](https://www.sectoralpha.in/us/stocks/md) MD · turning · Evidence leans up · 81% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 0.6% · Profit 61.5% · Operating margin change -0.2 points · 83% evidence Capital efficiency 14.6/25 · ROCE 14.8% · Operating margin 13.4% · 76% evidence Valuation 13.1/20 · P/E 11.6× · PEG 0.8 · 65% evidence Relative strength 15.2/20 · Lead over its industry 1.2% · Lead over S&P 500 23% · 1 year 39.5% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.4 + 14.6 + 13.1 + 15.2 = 62.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Healthcare Services Group, Inc.](https://www.sectoralpha.in/us/stocks/hcsg) HCSG · turning · Evidence leans up · 85% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 4% · Profit 100% · Operating margin change -3.2 points · 95% evidence Capital efficiency 14.5/25 · ROCE 17.7% · Operating margin 6.7% · 76% evidence Valuation 14.4/20 · P/E 13.4× · PEG 0.43 · 65% evidence Relative strength 12.6/20 · Lead over its industry -4.8% · Lead over S&P 500 15.9% · 1 year 48.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 14.4 + 12.6 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Encompass Health Corporation](https://www.sectoralpha.in/us/stocks/ehc) EHC · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.5% · Profit 20.2% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.1/25 · ROCE 17% · Operating margin 18.1% · 76% evidence Valuation 12.4/20 · P/E 16.2× · PEG 0.8 · 65% evidence Relative strength 12.9/20 · Lead over its industry -4.8% · Lead over S&P 500 16.2% · 1 year 16.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 18.1 + 12.4 + 12.9 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) NUTX · leader · Evidence leans up · 64% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 6.8% · Profit 100% · Operating margin change 44 points · 62% evidence Capital efficiency 18.6/25 · ROCE 56.8% · Operating margin 57.8% · 76% evidence Valuation 10.9/20 · P/E 6.5× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -5.5% · Lead over S&P 500 14.2% · 1 year 56.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.5 + 18.6 + 10.9 + 8.3 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aveanna Healthcare Holdings Inc.](https://www.sectoralpha.in/us/stocks/avah) AVAH · leader · Too little evidence to rank firmly · 58% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.3/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 45% evidence Capital efficiency 15.3/25 · ROCE 17.7% · Operating margin 12.6% · 76% evidence Valuation 10.7/20 · P/E 7.2× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 14.4% · Lead over S&P 500 37.9% · 1 year 51.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 15.3 + 15.3 + 10.7 + 18.2 = 59.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Addus HomeCare Corporation](https://www.sectoralpha.in/us/stocks/adus) ADUS · turning · Evidence leans up · 81% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 15.9% · Profit 27.7% · Operating margin change 0.3 points · 83% evidence Capital efficiency 12.9/25 · ROCE 11.4% · Operating margin 9.7% · 76% evidence Valuation 13.0/20 · P/E 17.4× · PEG 0.67 · 65% evidence Relative strength 10.7/20 · Lead over its industry -8.5% · Lead over S&P 500 11.9% · 1 year 11.9% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21 + 12.9 + 13 + 10.7 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [HCA Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/hca) HCA · breaking out · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 7.3% · Profit 14.6% · Operating margin change -0.7 points · 83% evidence Capital efficiency 19.9/25 · ROCE 26.3% · Operating margin 15.2% · 76% evidence Valuation 14.3/20 · P/E 12.6× · PEG 0.49 · 65% evidence Relative strength 7.2/20 · Lead over its industry -21.2% · Lead over S&P 500 -2.7% · 1 year -2.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 19.9 + 14.3 + 7.2 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) UHS · losing its lead · Evidence leans up · 81% evidence 56.3 out of 100 Growth Capital Valuation Relative
12. [LifeStance Health Group, Inc.](https://www.sectoralpha.in/us/stocks/lfst) LFST · turning · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative
13. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) NHC · quiet · Evidence leans up · 81% evidence 54.0 out of 100 Growth Capital Valuation Relative
14. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) PACS · quiet · Evidence leans up · 71% evidence 53.7 out of 100 Growth Capital Valuation Relative
15. Fresenius Medical Care AG this page FMS · basing · Evidence leans up · 81% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.9/35 · Revenue -0.5% · Profit 43% · Operating margin change 2.6 points · 83% evidence Capital efficiency 11.1/25 · ROCE 8.3% · Operating margin 10.8% · 76% evidence Valuation 15.3/20 · P/E 11.3× · PEG 0.23 · 65% evidence Relative strength 2.4/20 · Lead over its industry -26.8% · Lead over S&P 500 -10.2% · 1 year -9.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 21.9 + 11.1 + 15.3 + 2.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 16. [Chemed Corporation](https://www.sectoralpha.in/us/stocks/che) CHE · quiet · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative
17. [Guardian Pharmacy Services, Inc.](https://www.sectoralpha.in/us/stocks/grdn) GRDN · quiet · Evidence leans down · 64% evidence 49.3 out of 100 Growth Capital Valuation Relative
18. [Surgery Partners, Inc.](https://www.sectoralpha.in/us/stocks/sgry) SGRY · turning · Evidence leans down · 64% evidence 48.8 out of 100 Growth Capital Valuation Relative
19. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) DVA · turning · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
20. [Astrana Health, Inc.](https://www.sectoralpha.in/us/stocks/asth) ASTH · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
21. [The Pennant Group, Inc.](https://www.sectoralpha.in/us/stocks/pntg) PNTG · turning · Evidence leans down · 81% evidence 43.9 out of 100 Growth Capital Valuation Relative
22. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) ENSG · turning · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
23. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) AGL · quiet · Evidence leans down · 64% evidence 41.2 out of 100 Growth Capital Valuation Relative
24. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) OPCH · breaking out · Evidence leans down · 81% evidence 41.0 out of 100 Growth Capital Valuation Relative
25. [Acadia Healthcare Company, Inc.](https://www.sectoralpha.in/us/stocks/achc) ACHC · quiet · Evidence leans down · 71% evidence 37.5 out of 100 Growth Capital Valuation Relative
26. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) USPH · leader · Evidence leans down · 81% evidence 36.3 out of 100 Growth Capital Valuation Relative
27. [Sonida Senior Living, Inc.](https://www.sectoralpha.in/us/stocks/snda) SNDA · basing · Evidence leans down · 64% evidence 36.2 out of 100 Growth Capital Valuation Relative
28. [Ardent Health, Inc.](https://www.sectoralpha.in/us/stocks/ardt) ARDT · losing its lead · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Brookdale Senior Living Inc.](https://www.sectoralpha.in/us/stocks/bkd) BKD · quiet · Most evidence points down · 64% evidence 32.8 out of 100 Growth Capital Valuation Relative
30. [Select Medical Holdings Corporation](https://www.sectoralpha.in/us/stocks/sem) SEM · Too little evidence to rank firmly · 36% evidence 50.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Care Facilities](https://www.sectoralpha.in/us/sectors/medical-care-facilities), all 30 compared on one page. ## Which companies are close to Fresenius Medical Care AG in size? Fresenius Medical Care AG is the 5th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Tenet Healthcare Corporation, Encompass Health Corporation and DaVita Inc. Just below it: The Ensign Group, Inc., Universal Health Services, Inc. and PACS Group, Inc. ### Medical Care Facilities companies close in size

1. [Tenet Healthcare Corporation](https://www.sectoralpha.in/us/stocks/thc) $21.2 billion
2. [Encompass Health Corporation](https://www.sectoralpha.in/us/stocks/ehc) $13.3 billion
3. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) $11.5 billion
4. Fresenius Medical Care AG $11.1 billion
5. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) $10.5 billion
6. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) $10.4 billion
7. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) $7.4 billion

[All 38 Medical Care Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/medical-care-facilities#all-companies)

### Companies close in size in other industries

1. [SK Telecom Co., Ltd.](https://www.sectoralpha.in/us/stocks/skm) $12 billion · Telecom Services
2. [Mueller Industries, Inc.](https://www.sectoralpha.in/us/stocks/mli) $12 billion · Metal Fabrication
3. Fresenius Medical Care AG $12 billion
4. [BWX Technologies, Inc.](https://www.sectoralpha.in/us/stocks/bwxt) $12 billion · Aerospace & Defense
5. [Freedom Holding Corp.](https://www.sectoralpha.in/us/stocks/frhc) $11.9 billion · Financial Conglomerates

## What else do people ask about Fresenius Medical Care AG? ### What were Fresenius Medical Care AG's latest quarterly results? Fresenius Medical Care AG reported revenue of $4.9 B and net profit of $218 M for the Jun 2026 quarter. Revenue rose 1.4% and profit fell 3.1% compared with a year earlier. Earnings per share were $0.81. The operating margin was 10.8%, 2.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Fresenius Medical Care AG's market cap? Fresenius Medical Care AG's market capitalisation is $11.1 B at a stock price of $21.73. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Fresenius Medical Care AG performing? Fresenius Medical Care AG's share price has been falling for 11 weeks. In its latest quarter, revenue rose 1.4% and profit fell 3.1% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 10 weeks running (as of 3 November 2026). ### Will Fresenius Medical Care AG's stock price go up? This page does not forecast Fresenius Medical Care AG's stock price. What it shows instead: the stock price is $21.73, and it has been falling for 11 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Is Fresenius Medical Care AG's profit real cash? Yes, over the last 3 years, 382% of Fresenius Medical Care AG's reported profit came in as cash from operations. The latest year was lower at 274%, so the trend is worth watching. In FY25, operating cash was $2.7 B against reported profit of $978 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Fresenius Medical Care AG in its business cycle? Fresenius Medical Care AG's FY25 operating margin was 9.5%, against a 5-year range of 7.8% to 10.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 10.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Fresenius Medical Care AG story? The main question: yearly earnings per share moved +83.6% while the share price moved −19.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Fresenius Medical Care AG a stock worth studying right now? What the numbers show: Fresenius Medical Care AG's earnings have grown faster than its share price. Earnings per share grew +83.6% in a year while the price moved −19.0%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.